Peterson B, Arzika AM, Amza A, Maliki R, Karamba AMankara, Moussa M, Kemago M, Liu Z, Houpt E, Liu J et al..  2024.  Assessment of spillover of antimicrobial resistance to untreated children 7 to 12 years old after mass drug administration of azithromycin for child survival in Niger: a secondary analysis of the MORDOR cluster-randomized trial.. Clin Infect Dis. 

Yan D, N Prajna V, Lalitha P, Sansanayudh W, Satitpitakul V, Laovirojjanakul W, Chaudhary M, Bountogo M, Sie A, Coulibaly B et al..  2024.  Association of weather variables with pathogens contributing to conjunctivitis worldwide.. Clin Infect Dis. 

O'Brien KS, Arzika AM, Amza A, Maliki R, Aichatou B, Bello IMamane, Beidi D, Galo N, Harouna N, Karamba AM et al..  2024.  Azithromycin to Reduce Mortality - An Adaptive Cluster-Randomized Trial.. N Engl J Med. 391(8):699-709.

Amza A, Kadri B, Nassirou B, Arzika A, Gebreegziabher E, Hu H, Zhong L, Chen C, Yu D, Abraham T et al..  2024.  Seroepidemiology of trachoma in a low prevalence region receiving annual mass azithromycin distribution in Maradi, Niger.. PLoS Negl Trop Dis. 18(12):e0012727.

Amza A, Nassirou B, Kadri B, Ali S, Mariama B, Ibrahim CMamadou, Roufaye LAboubacar, Lebas E, Colby E, Zhong L et al..  2023.  Comprehensive Profile of Pathogens and Antimicrobial Resistance in Conjunctivitis Cases from Niger.. Am J Trop Med Hyg. 109(6):1333-1338.

Ousmane S, Kollo IA, Jambou R, Boubacar R, Arzika AM, Maliki R, Amza A, Liu Z, Lebas E, Colby E et al..  2023.  Wastewater-Based Surveillance of Antimicrobial Resistance in Niger: An Exploratory Study.. Am J Trop Med Hyg. 

O'Brien KS, Arzika AM, Amza A, Maliki R, Ousmane S, Kadri B, Nassirou B, Mankara AKaramba, Harouna ANaser, Colby E et al..  2021.  Age-based targeting of biannual azithromycin distribution for child survival in Niger: an adaptive cluster-randomized trial protocol (AVENIR).. BMC Public Health. 21(1):822.